Skip to main content
SpringerLink
Log in

Primär nodales follikuläres Lymphom mit sekundärer kutaner Manifestation

First-line-Rituximab-Monotherapie

Primary nodal follicular lymphoma with secondary cutaneous manifestations

First-line rituximab monotherapy

  • Kasuistiken
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Non-Hodgkin-Lymphome (NHL) stellen eine heterogene Gruppe lymphoproliferativer Erkrankungen mit deutlich steigender Inzidenz dar. Das follikuläre Lymphom (FL) repräsentiert dabei mit ca. 22% aller Fälle die zweithäufigste Entität dieser Gruppe. Die Einführung des CD20-spezifischen monoklonalen Antikörpers „Rituximab“ hat die Behandlung des FL revolutioniert. Entsprechend den aktuellen europäischen Leitlinien wird Rituximab als obligater Teil einer First-line-Behandlung in Kombination mit Polychemotherapie beim fortgeschrittenen FL empfohlen sowie als Monotherapie nach Rezidiv zur Verlängerung der Remission. Dieser Beitrag beschreibt die First-line-Monotherapie mit Rituximab (ohne kombinierte Chemotherapie) eines primär nodalen disseminierten FL mit kutaner Manifestation.

Abstract

Non-Hodgkin lymphomas (NHL) comprise a heterogeneous collection of lymphoproliferative malignancies. Follicular lymphoma (FL) is the second most common NHL sub-type. Over the last years, the introduction of the anti-CD20 monoclonal antibody rituximab has radically changed treatment of FL. After several large prospective randomized trials demonstrated prolongation of remission, current European indications for rituximab include the first-line treatment of patients with stage III-IV FL in combination with polychemotherapy such as CVP or CHOP. This paper discusses the treatment of primary nodal FL with secondary cutaneous involvement with rituximab as monotherapy without additional chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106

    Article  CAS  PubMed  Google Scholar 

  2. Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725–3732

    Article  CAS  PubMed  Google Scholar 

  3. Kerl K, Prins C, Saurat JH, French LE (2006) Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155:1197–1200

    Article  CAS  PubMed  Google Scholar 

  4. Fridrik MA (2008) Maligne Lymphome im Erwachsenenalter. Dtsch Med Wochenschr 133:2109–2114

    CAS  PubMed  Google Scholar 

  5. Marcus RE, Solal-Celigny P, Imrie K et al (2006) MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin’s lymphoma. Blood ASH Annu Meet 108:481

    Google Scholar 

  6. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26(5 Suppl 14):79–87

    CAS  PubMed  Google Scholar 

  7. Sacchi S, Pozzi S, Marcheselli L et al (2007) Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 109:2077–2082

    Article  CAS  PubMed  Google Scholar 

  8. Solal-Céligny P, Roy P, Colombat P, White J et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265

    Article  PubMed  Google Scholar 

  9. Solal-Celigny P, Salles GA, Brousse N et al (2004) Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma: survival analyses with a follow-up of at least years. Blood ASH Annu Meet 104:585

    Google Scholar 

  10. Witzig TE, Vukov AM, Habermann TM et al (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103–1108

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Eduard-Arning-Klinik für Dermatologie und Allergologie, Asklepios Klinik St.Georg, Lohmühlenstr. 5, 20099, Hamburg, Deutschland

    R. Koch & C.A. Sander

Authors
  1. R. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.A. Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Koch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koch, R., Sander, C. Primär nodales follikuläres Lymphom mit sekundärer kutaner Manifestation. Hautarzt 61, 976–979 (2010). https://doi.org/10.1007/s00105-009-1902-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-009-1902-2

Schlüsselwörter

Keywords

Search

Navigation